18 March 2020 - Biohaven Pharmaceutical announced today that the Company's myeloperoxidase inhibitor, verdiperstat, received Fast Track designation from the US FDA for the treatment of multiple system atrophy.
Verdiperstat is a potential first-in-class, oral, brain-penetrant, irreversible inhibitor of myeloperoxidase, an enzyme that acts as a key driver of pathological oxidative stress and inflammation in the brain.